[Media Releases] LegoChem to become a global pharmaceutical company with Korea’s best R&D personnel and profits from licensing-out (Daejon Ilbo, 15 Oct 2014)
Title: LegoChem to become a global pharmaceutical company with Korea’s best R&D personnel and profits from licensing-out Publication: Daejon ilbo / Dae-Ho Kim Date: 15 Oct 2014 URL: link to website (contents in Korean)
· Since its inception in 2006, LegoChem has been a biopharmaceutical company specializing in medicinal chemistry, and technology for discovering and developing new drugs has been the core strength and the profit generating factor. · With its core therapeutic areas including antibiotics, anti-coagulants, anti-cancer, and next-generation Antibody-Drug Conjugates (ADCs) technology, LegoChem is collaborating with or out-licensing to global and national pharmaceutical companies. · LegoChem is expected to become a leading venture firm in the future local economy, and it has a long-term vision to grow into a global pharmaceutical company based on its key expertise in drug discovery, adding production and marketing capability.
About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |